AKBA (Akebia Therapeutics) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKBA Akebia Therapeutics Inc AKBA
47 GF Score
Price $1.38
GF Value $1.28
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

AKBA
47GF Score
Akebia Therapeutics Inc AKBA
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Akebia Therapeutics (AKBA) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of $1.38 is trading 7.8% above its estimated GF Value™ of $1.28. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for AKBA:

  • Dividends Received:
  • GF Value™: $1.28 vs. price of $1.38 (7.8% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the AKBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AX9:Germany
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
47GF Score

Get the complete analysis for AKBA

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price
$1.28
GF Value